National Cancer Institute; Notice of Closed Meetings, 4674 [2020-01255]
Download as PDF
<![CDATA[
4674
Federal Register / Vol. 85, No. 17 / Monday, January 27, 2020 / Notices
Place: The Ritz Carlton Hotel, 1700 Tysons
Boulevard, Conference Room: Old Dominion,
McLean, VA 22102.
Contact Person: Christine A. Livingston,
Ph.D., Scientific Review Officer, Office of
Scientific Review, National Center for
Advancing Translational Sciences (NCATS),
National Institutes of Health, 6701
Democracy Blvd., Democracy 1, Room 1073,
Bethesda, MD 20892, (301) 435–1348,
livingsc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: January 21, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–01257 Filed 1–24–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI U01
Review: Integrating Biospecimen Science
Approaches into Clinical Assay.
Date: February 26, 2020.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W244, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: John Paul Cairns, Ph.D.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, 9609 Medical Center Drive, Room
7W244, National Cancer Institute, NIH,
Bethesda, MD 20892, 240–276–5415,
paul.cairns@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Improving
VerDate Sep<11>2014
16:54 Jan 24, 2020
Jkt 250001
Outcomes for Pediatric, Adolescent and
Young Adult Cancer Survivors (U01).
Date: March 17, 2020.
Time: 10:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W618, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Mukesh Kumar, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, 9609 Medical Center Drive, Room
7W618, National Cancer Institute, NIH,
Rockville, MD 20850 240–276–6611,
mukesh.kumar3@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; R13
Conference Grant Review.
Date: April 2, 2020.
Time: 10:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W554, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Christopher L. Hatch,
Ph.D., Chief, Program Coordination &
Referral Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W554,
Rockville, MD 20850, 240–276–6454, ch29v@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: January 21, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–01255 Filed 1–24–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke, Muscular
Dystrophy Coordinating Committee
Call for Committee Membership
Nominations
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Office of the Secretary of
the Department of Health and Human
Services (HHS) is seeking nominations
for an individual to serve as a
nonfederal public member on the
SUMMARY:
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
Muscular Dystrophy Coordinating
Committee.
DATES: Nominations are due by 5:00
p.m. EDT on February 28, 2020.
ADDRESSES: Nominations must be sent
to Glen Nuckolls, Ph.D., by email to
nuckollg@ninds.nih.gov.
FOR FURTHER INFORMATION CONTACT: Glen
Nuckolls, Ph.D., by email to nuckollg@
ninds.nih.gov. or (301) 496–5745.
SUPPLEMENTARY INFORMATION: The
Muscular Dystrophy Coordinating
Committee (MDCC) is a federal advisory
committee established in accordance
with the Muscular Dystrophy
Community Assistance, Research, and
Education Amendments of 2001 (MD–
CARE Act; Pub. L. 107–84). The MD–
CARE Act was reauthorized in 2008 by
Public Law 110–361, and again in 2014
by Public Law 113–166. The MD–CARE
Act specifies that the committee
membership be composed of 2⁄3
governmental agency representatives
and 1⁄3 public members. We are seeking
nominations for four non-federal, public
members at this time, due to turnover of
committee membership. Nominations
will be accepted between January 28
and February 28, 2020.
Who is Eligible: Nominations are
encouraged for new or reappointment of
non-federal public members who can
provide the public and/or patient
perspectives to discussions of issues
considered by the Committee. Selfnominations and nominations of other
individuals are both permitted. Only
one nomination per individual is
required. Multiple nominations for the
same individual will not increase
likelihood of selection. Non-federal,
public members may be selected from
the pool of submitted nominations or
other sources as needed to meet
statutory requirements and to form a
balanced committee that represents the
diversity within the muscular dystrophy
communities. Nominations are
especially encouraged from leaders or
representatives of muscular dystrophy
research, advocacy, or service
organizations, individuals with
muscular dystrophy or their parents or
guardians. In accordance with White
House Office of Management and
Budget guidelines (FR Doc. 2014–
19140), federally-registered lobbyists are
not eligible.
Committee Composition: The
Department strives to ensure that the
membership of HHS Federal advisory
committees is fairly balanced in terms of
points of view represented and the
committee’s function. Every effort is
made to ensure that the views of all
genders, all ethnic and racial groups,
and people with disabilities are
E:\FR\FM\27JAN1.SGM
27JAN1
]]>Agencies
[Federal Register Volume 85, Number 17 (Monday, January 27, 2020)]
[Notices]
[Page 4674]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-01255]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI U01 Review: Integrating Biospecimen Science Approaches
into Clinical Assay.
Date: February 26, 2020.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W244, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: John Paul Cairns, Ph.D., Scientific Review
Officer, Research Programs Review Branch, Division of Extramural
Activities, 9609 Medical Center Drive, Room 7W244, National Cancer
Institute, NIH, Bethesda, MD 20892, 240-276-5415,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; Improving Outcomes for Pediatric, Adolescent and Young Adult
Cancer Survivors (U01).
Date: March 17, 2020.
Time: 10:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W618, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Mukesh Kumar, Ph.D., Scientific Review Officer,
Research Program Review Branch, Division of Extramural Activities,
9609 Medical Center Drive, Room 7W618, National Cancer Institute,
NIH, Rockville, MD 20850 240-276-6611, [email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; R13 Conference Grant Review.
Date: April 2, 2020.
Time: 10:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W554, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Christopher L. Hatch, Ph.D., Chief, Program
Coordination & Referral Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W554, Rockville, MD 20850, 240-276-6454, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: January 21, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-01255 Filed 1-24-20; 8:45 am]
BILLING CODE 4140-01-P
